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Abbreviations
and Acronyms
CMR = cardiac magnetic
resonance
CRT = cardiac
resynchronization therapy
CURE = circumferential
uniformity ratio estimate
DENSE = displacement
encoding with stimulated
echoes
ECC = circumferential strain
LGE = late gadolinium
enhancement
LV = left ventricle/
ventricular
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular
ejection fraction
LVESV = left ventricular
end-systolic volume
LVLP = left ventricular lead
position
QLV = QRS to left ventricular
electrogram interval
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1658Outcomes after cardiac resynch-
ronization therapy (CRT) are
inﬂuenced by a complex interac-
tion between the myocardial
substrate and the left ventricular
lead position (LVLP). The myo-
cardial substrate may be charac-
terized both by the pattern of
mechanical activation (1) and the
distribution of scar (2). Recent
echocardiographic methods such
as 3-dimensional echocardiogra-
phy and speckle tracking (3,4)
offer the potential for better per-
formance than previous methods,
as do dyssynchrony assessments
based on cardiac magnetic reso-
nance (CMR) (5) and the cir-
cumferential uniformity ratio
estimate (CURE) (6–8). Scar in
the posterolateral left ventricle
(LV), a common location for
the LV lead, has been associ-
ated with CRT nonresponse (9),
whereas late-activated sites based
on electrical parameters (LV leadelectrical delay and QRS to left ventricular intrinsic acti-
vation interval [QLV]) (10,11) or mechanical criteria
(12,13) appear to be better locations for LV leads.
CMR is the gold standard for assessment of myocardial
scar. We have recently shown that CMR displacement
encoding with stimulated echoes (DENSE) generates high-
quality circumferential strain data (5,8,14–16) that can pre-
cisely describe the state of mechanical dyssynchrony using
the CURE parameter (6), which does not require manual
detection of regional time to peak strain (8). We now report
the results of a cohort study of patients referred for CRT
based on the hypothesis that favorable CMR ﬁndings (lower
CURE from CMR DENSE, no scar at the LVLP, and
delayed onset of circumferential contraction at the LVLP)
and late electrical activation at the LVLP are strongly asso-
ciated with CRT response and clinical events during follow-
up. The clinical signiﬁcance is that CMR applied this way
could improve upon current criteria for patient selection
(17,18) and facilitate more effective implementation of CRT.Methods
Cohort selection. The study was approved by the Institu-
tional Review Board for Human Subjects Research at the
University of Virginia. Patients were required to have a
clinical indication for CRT based on established guidelines
(18) and a glomerular ﬁltration rate of at least 45 ml/min/
1.73 m2 in order to receive gadolinium.
CMR protocol. Prior to the CRT procedure, patients
underwent a research CMR protocol including steady-statefree precession imaging, cine DENSE imaging, and late
gadolinium enhancement (LGE) on a 1.5-T Avanto scanner
(Siemens Healthcare, Erlangen, Germany) with a 4-channel
phased-array chest radiofrequency coil. Cine DENSE im-
aging (previously validated by comparison with myocardial
tagging in heart failure) (8) was performed in 4 short-axis
and 3 long-axis planes with displacement encoding applied
in 2 orthogonal in-plane directions for each plane with the
following parameters (14,15): interleaved spiral readout with
6 interleaves per image; repetition time/echo time 17 ms/
1.9 ms; slice thickness 8 mm; ﬁeld of view 350  350 mm;
ﬂip angle 15; pixel size 2.8  2.8 mm; fat suppression; and
displacement-encoding frequency 0.1 cycles/mm.
Determination of echocardiographic volumes before and
after CRT. Standard 2D echocardiographic images with
Doppler were obtained for all patients at baseline and 3
months and 6 months after CRT with standard short- and
long-axis views. The left ventricular end-systolic volume
(LVESV), left ventricular end-diastolic volume (LVEDV),
and left ventricular ejection fraction (LVEF) before and
after CRT were determined using Simpson’s rule for 2-
and 4-chamber long-axis views using EchoPAC software
(GE, Fairﬁeld, Connecticut).
Clinical CRT procedure. Patients then underwent the
clinical CRT procedure. During the procedure, venograms
of the coronary sinus were recorded in 2 projections. Final
cine images of the leads were recorded in the usual left
anterior oblique, anterior-posterior, and right anterior obli-
que projections.
Clinical follow-up and determination of CRT response.
The echocardiographic evaluation at 3 months included
standard A-V and V-V optimization. CRT response was
deﬁned as a 15% reduction in LVESV at 6 months (or the
last follow-up echocardiogram prior to death if the patient
died prior to 6 months after implantation). After the pro-
cedure, subsequent clinic notes, device interrogations, and
discharge summaries for inpatient hospitalizations were
reviewed for all study patients. Sustained ventricular tachy-
arrhythmia events were deﬁned as episodes of ventricular
tachycardia or ventricular ﬁbrillation requiring implantable
cardioverter-deﬁbrillator therapies or untreated ventricular
tachyarrhythmia episodes >30 s detected by the implantable
cardioverter-deﬁbrillator, and these events were also recor-
ded in the database.
CMR DENSE image processing and strain analysis.
Following image acquisition, segmentation of the LV
myocardium was performed semiautomatically for cine
DENSE images (19), a phase-unwrapping algorithm was
applied to LV myocardium pixels, and displacements were
calculated (5). Lagrangian strain was computed from dis-
placements in 24 short-axis segments in multiple slices and
was then projected in both the radial and circumferential
(circumferential strain [ECC]) directions relative to the LV
center of mass. LV volumes, mass, and ejection fraction were
calculated from cine steady-state free precession images us-
ing Argus software (Siemens, Erlangen, Germany).
Figure 1 Scar and Time to ECC Onset for 3 CRT Responders
(A) Patient with dyssynchrony, no scar, and delayed circumferential strain (ECC) onset at the left ventricular lead position (LVLP, denoted as X in the ﬁgure). (B) Patient with
dyssynchrony, anteroseptal infarct, and delayed ECC onset at the LVLP. (C) Patient with dyssynchrony, posterolateral infarct, and LVLP in an anterolateral segment with delayed
ECC onset and no scar. CRT ¼ cardiac resynchronization therapy; CURE ¼ circumferential uniformity ratio estimate; LGE ¼ late gadolinium enhancement.
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1659Evaluation of CMR dyssynchrony, strain onset at the
LVLP, and electrical activation at the LVLP. Dyssyn-
chrony was assessed from 4 short-axis cine DENSE slices at
basal, midbasal, midapical, and apical levels (with additional
weight given to basal and midbasal slices) using CURE,
which is based on the Fourier transform (FT) of the spatial
distribution of strain as previously described (6–8). Brieﬂy,
CURE makes use of the zero-order power and ﬁrst-order
power from the Fourier analysis of this function to index
dyssynchrony on a scale between 0 (dyssynchrony) and 1
(synchrony) (6). The characteristics of the ECC curve at the
LV lead implantation site were then determined with respect
to time to peak ECC and onset of ECC (onset of circum-
ferential contraction), which was deﬁned as the time from
QRS detection by the scanner’s gating software (when
DENSE encoding pulse are applied) to the onset of a
negative slope of the ECC curve. Regarding electrical acti-
vation, the QLV was calculated, as previously described, as
the time from QRS onset to the electrogram at the LVLP,with a value of at least 95 ms associated with greater rates of
CRT response in the SMART-AV (SmartDelay deter-
mined AV Optimization) trial (11).
Evaluation of myocardial scar from LGE and lead
position relative to scar. The lead position relative to scar
from CMRLGEwas determined using the “o’clock”method
in all patients (20). In a subset of these patients, results from
this method were also conﬁrmed using a quantitative algo-
rithm we developed and validated for lead localization, as
previously described (21). Regarding the latter, we pre-
calibrated standard ﬂuoroscopy suites by imaging a phan-
tom at multiple camera positions, then reconstructed and
registered 3-dimensional lead positions with pre-procedure
CMR. With this method, the LVLP was identiﬁed as the
point on the epicardial surface at which the distances between
the lead position and each of the 3 landmarks (coronary sinus
ostium, RV apex, and anterolateral mitral annulus) in the
CMR coordinate space were most similar to the equivalent
distances in the ﬂuoroscopic space. This algorithm was
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1660implemented in custom software written using Matlab
version 7.14 (The Mathworks, Natick, Massachusetts).
In patients with previous myocardial infarction, scar was
manually segmented from short-axis LGE images using the
segmentation software Segment described previously. LGE
tissue (scar tissue) had a signal intensity at least 2 SDs above
the mean signal intensity in remote areas. Scar transmurality
was measured as a fraction of wall thickness calculated over
the circumference with a 5 moving average window, using
custom software implemented in Matlab. Scar distribution
and transmurality were displayed on a Hammer projection
map of the epicardial surface (22) along with the LVLP, as
shown in Figures 1 and 2.
Statistical analysis. Statistical analysis was performed
using SAS version 9.3 (SAS Institute, Cary, North Car-
olina). The Wilcoxon 2-sample test (Mann-Whitney
U test) was used for univariate comparisons between
continuous variables, and the Fisher exact test was used forFigure 2 Scar and Time to ECC Onset for 3 CRT Nonresponders
(A) Patient with minimal dyssynchrony and LVLP (LV lead position, denoted as X in the ﬁ
associated with posterolateral infarction and LVLP in scar. (C) Patient with right bundle-b
borderline dyssynchrony, no scar, and LVLP in early-activated segment. The late anteroseunivariate comparisons between categorical variables (as
in Table 1).
Based on the hypothesis that CRT response would be
strongly associated with overall dyssynchrony with CURE
(continuous), mechanical stretch (delayed ECC onset) at the
LVLP (categorical), scar at the LVLP (categorical), and late
electrical activation at the LVLP (continuous), bivariable
logistic regression was used to estimate the probability of a
15% reduction in LVESV associated with these variables.
Based on prior associations between scar burden and CRT
outcomes (2), LV percent scar volume (continuous) was also
analyzed using bivariable logistic regression, as was the LV
mass index (continuous) parameter (based on a proposed
mechanistic association between LV mass and CRT out-
comes). Receiver-operating characteristic (ROC) analysis
was also performed, and the statistical signiﬁcance of the
area under the curve (AUC) was determined based on
comparison with chance. Multivariable logistic regressiongure) in anterolateral segment with scar. (B) Patient with borderline dyssynchrony
ranch block (RBBB)/left anterior fascicular block (LAFB) with QRS duration 180 ms,
ptal activation is associated with bifascicular block. Abbreviations as in Figure 1.
Table 1 Baseline Characteristics of CRT Responders and Nonresponders
All
(N ¼ 75)
Responders
(n ¼ 40)
Nonresponders
(n ¼ 35) p Value
Demographic/clinical
Age, yrs 65.9 (57.8–74.3) 65.3 (57.7–72.6) 67.9 (59.2–76.4) 0.35
Female 19 (25.3) 16 (40.0) 3 (8.6) 0.003
NYHA functional
class II/III/IV
3 (4.0)/71 (94.7)/1 (1.3) 3 (7.5)/37 (92.5)/0 (0) 0 (0)/34 (97.1)/1 (2.9) 0.17
CMR imaging
parameters
LVEF, % 23.2 (15.0–28.4) 22.8 (16.1–27.9) 23.2 (13.8–28.4) 0.81
LVEDV index, ml 122 (104.1–151.0) 110.0 (91.4–139.3) 133.7 (110.5–155.6) 0.007
LVESV index, ml 96.9 (78.0–126.4) 88.0 (71.6–116.1) 109.3 (86.8–136.6) 0.02
SV index, ml 26.8 (21.2–33.9) 26.1 (21.0–28.0) 31.0 (24.0–38.0) 0.03
LV mass index, g/m2 70.9 (59.4–82.9) 63.6 (49.5–80.7) 74.6 (66.0–90.2) 0.006
LGE present 41 (54.7) 17 (42.5) 24 (68.6) 0.04
LV scar volume, % 4.3 (0–12.7) 0 (0–12.3) 7.3 (0–12.9) 0.12
CURE 0.61 (0.36–0.74) 0.37 (0.26–0.61) 0.75 (0.64–0.81) <0.0001
Electrical, mechanical,
and scar properties
at LV lead
QLV 108 (72–140) 125 (107–143) 90 (60–105) 0.0002
Lead position in scar 28 (37.3) 8 (20.0) 20 (57.1) 0.002
Initial mechanical
stretch
43 (57.3) 29 (72.5) 14 (40) 0.006
ECG parameters
QRS duration, ms 155 (140–170) 160 (150–172) 150 (134–170) 0.12
LBBB 67 (89.3) 39 (97.5) 28 (80.0) 0.02
Comorbid conditions
Prior MI 34 (45.3) 14 (35.0) 20 (57.1) 0.06
Prior CABG 9 (12.0) 4 (10.0) 5 (14.3) 0.72
Chronic kidney
disease
15 (20.0) 10 (25.0) 5 (14.3) 0.38
Diabetes mellitus 21 (28.0) 9 (22.5) 11 (34.3) 0.30
Peripheral arterial
disease
9 (12.0) 3 (7.5) 6 (17.1) 0.28
Hypertension 41 (54.7) 24 (60.0) 17 (48.6) 0.36
Prior stroke/TIA 7 (9.3) 5 (12.5) 2 (5.7) 0.43
Obstructive sleep
apnea
15 (20.0) 7 (17.5) 8 (22.9) 0.58
Events during follow-up
Death 16 (21.3) 2 (5.0) 14 (40.0) 0.0004
Sustained VT 12 (16.0) 2 (5.0) 10 (28.6) 0.01
HF hospitalization 20 (26.7) 3 (7.5) 17 (48.6) <0.0001
Values are median (interquartile range) or n (%). The numbers in parentheses for New York Heart Association (NYHA) functional class are the
percentages of patients in each class.
CABG ¼ coronary artery bypass graft; CMR ¼ cardiac magnetic resonance; CRT ¼ cardiac resynchronization therapy; CURE ¼ circumferential
uniformity ratio estimate; ECG ¼ electrocardiogram; LBBB ¼ left bundle branch block; LGE ¼ late gadolinium enhancement; LV ¼ left ventricle/
ventricular; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume;
MI ¼myocardial infarction; QLV ¼ QRS to left ventricular electrogram interval; SV ¼ stroke volume; TIA ¼ transient ischemic attack; VT ¼ ventricular
tachyarrhythmia.
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1661was then performed based on this hypothesis-driven model
with CURE, mechanical stretch at the LVLP (delayed ECC
onset), scar at the LVLP, and late electrical activation at the
LVLP. Multivariable linear regression was then performed
to estimate the percent change in LVESV as a variable
function of these same 4 selected covariates from the
multivariable logistic regression model.
Overﬁtting was evaluated based on the heuristic shrinkage
estimator of van Houwelingen and le Cessiej, which
should be 0.90 to rule out overﬁtting (23). For themultivariable logistic model, the shrinkage estimator was
calculated as: (model likelihood chi-square statistic number
of covariates)/(model likelihood chi-square statistic). For the
multivariable linear model, the shrinkage estimator was
calculated as the ratio of the adjusted R2 to the raw R2 (23).
Kaplan-Meier plots, the log-rank statistic, and Cox
proportional hazards regression were used to analyze the
associations for mechanical and scar ﬁndings with the clin-
ical outcomes of death and sustained ventricular tachyar-
rhythmia events (as deﬁned in the previous text). For the
Table 2 Bivariable Logistic Regression for CRT Response
Covariate OR (95% CI)
Wald Chi-Square
(p Value) AUC (p Value) Sens./Spec.
Mechanical dyssynchrony
CURE
Continuous (0.1 decrease) 2.20 (1.56–3.16) 19.66 (<0.0001) 0.87 (<0.0001) d
Dichotomous (<0.70)* d d 0.82 (<0.0001) 100/65.7
LV lead position
Early mechanical stretch 3.95 (1.50–10.4) 7.73 (0.005) 0.66 (0.003) 72.5/60.0
Lead not in scar 5.33 (1.92–14.9) 10.27 (0.001) 0.69 (0.0005) 80.0/60.0
QLV
Continuous (10 ms) 1.31 (1.12–1.54) 11.67 (0.0006) 0.76 (<0.0001) 85.0/57.1
Dichotomous (95 ms) 6.73 (2.26–20.1) 11.68 (0.0006) 0.70 (0.0001)
Global LV structure
LV percent scar volume
Continuous (per 10%) 0.79 (0.52–1.21) 1.18 (0.28) 0.59 (0.16) d
Dichotomous (20%) 3.17 (0.574–17.5) 1.75 (0.19) 0.55 (0.18) 95.0/14.3
LV mass index
Continuous (per 10 g/m2) 0.75 (0.59–0.96) 5.44 (0.02) 0.68 (0.002)
Dichotomous (70 g/m2) 2.29 (0.904–5.80) 3.05 (0.08) 0.60 (0.08) 53.3/62.9
*Likelihood ratio could not be calculated due to 0% responders with CURE 0.70.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
Table 3
Multivariable Logistic Regression Model for
Echocardiographic CRT Response
Model Variable OR (95% CI)
Wald
Chi-Square p Value
CURE (per 0.1 decrease) 2.59 (1.58–4.23) 14.4 <0.0001
Lead position not in scar 14.9 (2.56–86.6) 9.03 0.003
Mechanical stretch at LVLP* 6.55 (1.18–36.4) 4.61 0.03
QLV (per 10-ms increase) 1.31 (1.04–1.65) 5.36 0.02
Maximum rescaled R2 ¼ 0.72, area under the curve 0.95 (p < 0.001). *Equivalent to delayed ECC
onset.
Abbreviations as in Tables 1 and 2.
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1662clinical outcome of death, patients having favorable values
for the CMR parameters in the multivariable logistic model
(CURE <0.70, no scar at the LVLP, and mechanical
stretch at the LVLP) were compared with patients without
this optimal CMR proﬁle. The threshold value for CURE
was based on a prior smaller study in a completely different
cohort of patients (6).
Results
The cohort included 75 patients who had either a Class I or
Class IIa indication for CRT according to current guidelines
(18) and underwent implantation of a CRT deﬁbrillator
with subsequent clinical follow-up (median follow-up 2.6
years). The baseline characteristics are given in Table 1 for
the entire cohort, as well as responders and nonresponders
(LVESV improvement of at least 15%). With respect to LV
structural characteristics based on CMR, the baseline LVEF
(23.2% [interquartile range (IQR): 15.0% to 28.4%]) was
similar in responders and nonresponders, but the baseline
LVESV index, baseline LVEDV index, stroke volume in-
dex, and baseline LV mass index were all greater in non-
responders versus responders. The frequency of comorbid
medical disease was also similar among responders and
nonresponders.
With respect to events during follow up, 21.3% of pa-
tients died during a median follow-up of 2.6 years (IQR: 1.6
to 3.8 years), whereas 16.0% had sustained ventricular
tachycardia or ﬁbrillation, and 26.7% were hospitalized with
heart failure. As shown in Table 1, the rates of all of these
events were much higher for nonresponders compared with
responders (p < 0.009 to 0.0001).
Based on echocardiography before and after CRT, favor-
able changes in LVESV, LVEDV, and LVEF wereconﬁrmed in responders but not in nonresponders. Although
signiﬁcant differences in LVESV are expected based on the
deﬁnition of CRT response, results for all 3 parameters by
group are reported for completeness. In responders, LVESV
decreased (LVESV percent change 32.5% [IQR: 49.5%
to22.2%]) and LVEF increased (absolute LVEF change of
16.5% [IQR: 9% to 23.5%]), whereas LVESV and LVEF
failed to improve in nonresponders (LVESV percent change
3.3% [IQR: 0.7% to 22.1%], median LVEF absolute
change4% [IQR:8% to 0%]) (p< 0.001 for comparisons
between responders and nonresponders). The LVEDV also
decreased in responders (LVEDV percent change 12.9%
[IQR: 27.6% to 4.4%]) but remained about the same in
nonresponders (LVEDV percent change 0.2% [IQR:3.7%
to 9.0%]) (p < 0.001 for comparisons between responders
and nonresponders).
As shown in Figures 1 and 2, mechanical and scar char-
acteristics of the LV as a whole and at the LVLP were
characterized in detail with cine DENSE and LGE. Figure 1
shows 3 examples of CRT responders, whereas Figure 2
shows 3 examples of CRT nonresponders. Consistent with
our hypothesis, the comparison of nonresponders and
Table 4
Multivariable Linear Regression Model for
Percent Change in LVESV
Model Variable
Model
Coefﬁcient
Standard
Error p Value
Standardized
Coefﬁcient
Intercept 0.201 0.115 0.08 0
CURE (0 to 1) 0.608 0.107 <0.0001 0.502
Lead position
not in scar
0.116 0.0472 0.02 0.209
Mechanical
stretch at LVLP*
0.0947 0.0483 0.05 0.172
QLV (ms) 0.00139 0.000679 0.05 0.185
R2 ¼ 0.53; adjusted R2 ¼ 0.50. *Equivalent to delayed ECC onset.
Abbreviations as in Tables 1 and 2.
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1663responders showed signiﬁcant differences not only in overall
mechanical dyssynchrony with CURE but also in mechanical
activation, electrical activation, and scar at the LVLP.
Bivariable logistic regression results for the 4 parameters
hypothesized to have strong associations with CRT response
(as well as the additional 2 variables of interest) are shown in
Table 2. The corresponding multivariable model with these
4 parameters identiﬁed in our hypothesis is shown in
Table 3. This model had an AUC of 0.95 (p < 0.0001)
without evidence of overﬁtting (shrinkage estimator ¼
0.931) (Fig. 3). The 4 covariates and corresponding odds
ratios (ORs) were: CURE for overall dyssynchrony (OR:
2.59 per 0.1 decrease in CURE [95% conﬁdence interval
(CI): 1.58 to 4.23], absence of scar at the LVLP (OR: 14.9
[95% CI: 2.56 to 86.6]), delayed onset of ECC at the LVLP
(OR: 6.55 [95% CI: 1.18 to 36.4]), and delayed electrical
timing at the LVLP based on the QLV (OR: 1.31 [95% CI:
1.04 to 1.65] per 10 ms increase in QLV), which was
determined as the time from the QRS onset to the intra-
procedural electrogram at the LVLP. The Nagelkerke
maximum rescaled R2 for the model was 0.72.
As shown in Table 4, the original covariates shown in the
multivariable logistic model in Table 3 were also strongly
associated with the percent change in LVESV (R2 ¼ 0.53)
in a multivariable linear model, again without overﬁtting
(shrinkage estimator ¼ 0.948) (23), consistent with an as-
sociation not only with the presence but also with the degree
of LV functional improvement. As shown in Figure 4, the
LVESV decreased by 23.4% (IQR: 17.1% to 44.9%) in
the 52 patients with CURE <0.70 but increased by 7.2%
(IQR: 2.9% to 24.7%) in 23 patients with CURE 0.70Figure 3 ROC Analysis for the Multivariable Logistic Model
The receiver-operating characteristic (ROC) curve is shown for the multivariable
logistic model in Table 3, as described in the text. AUC ¼ area under the curve.(p < 0.0001) (Fig. 4A). Regarding mechanical characteris-
tics at the LV lead site, in the 52 patients with signiﬁcant
dyssynchrony by CURE (<0.70), the 33 patients with
delayed ECC onset (mechanical stretch) at the LVLP had a
median decrease in the LVESV of 27.4% (IQR: 18.0% to
51.9%) after CRT, compared with 18.2% (IQR: 1.5% to
31.7%) in the 19 patients without delayed ECC onset at
the LVLP (p ¼ 0.01) (Fig. 4B). Furthermore, in the 38
patients with CURE <0.70 and no scar at the LVLP, all
25 patients with delayed ECC onset at the LVLP had a
CRT response with a decrease of 37.1% (IQR: 22.1% to
52.0%) in LVESV compared with a decrease of only 17.6%
(IQR: 2.5% to 22.4%) in the remaining patients without
delayed ECC onset at the LVLP (p ¼ 0.002) (Fig. 4D).
The multivariable logistic model for CRT response with
CMR parameters only (CURE, delayed onset of ECC at the
LVLP, absence of LVLP scar, and LV mass index) also
performed very well (p < 0.05 for maximum likelihood
estimates for all parameters), with an overall AUC of 0.94
(p < 0.0001) and Nagelkerke R2 ¼ 0.72 (p < 0.05)
(Online Table 1). In addition, the multivariable linear
model for percent change in LVESV including these same
CMR parameters (Online Table 2) also demonstrated
similar performance compared with the original model
reported in Table 4. Regarding scar burden, the LV percent
scar volume was not included in these models because it
was no longer associated with CRT response after adjust-
ment for the presence of scar at the LVLP.
In addition to the associations between CMR ﬁndings
and echocardiographic CRT response, favorable CMR
ﬁndings were also associated with better clinical outcomes,
as shown in the Kaplan-Meier curves for overall survival
(log-rank p ¼ 0.006) and ventricular tachyarrhythmias
(p ¼ 0.01) in Figures 5 and 6, respectively. Patients with
CURE 0.70 had a 12-fold increased risk of death (median
follow-up of 2.6 years) compared with the group with the
favorable CMR ﬁndings of CURE <0.70, absence of LVLP
scar, and delayed onset of ECC at the LVLP (hazard ratio:
11.9 [95% CI: 1.5 to 93.5]) (Fig. 5). In addition, patients
with CURE 0.60 had an increased risk of sustained ven-
tricular tachyarrhythmias after CRT (hazard ratio: 8.24
[95% CI: 1.06 to 63.9]) compared with patients with
CURE <0.60 (Fig. 6).
Figure 4 Box Plots for CRT Response in Selected Subgroups
(A) Greater cardiac resynchronization therapy (CRT) response is present with CURE <0.70. (B) Greater CRT response is present with delayed ECC onset at the LVLP among
patients with CURE <0.70. (C) Differences in CRT response with CURE <0.70 (as shown in A), including only patients without LVLP scar. (D) Compared with B, patients without
scar at the LVLP and CURE <0.70 have even more pronounced differences in CRT response based on the presence or absence of delayed ECC onset. LVESV ¼ left ventricular
end-systolic volume; other abbreviations as in Figure 1.
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The principal ﬁnding of this study was that both echocar-
diographic CRT response and clinical outcomes such as
death and sustained ventricular tachyarrhythmia after
CRT can be explained with an integrated model based onFigure 5 Survival Based on Favorable and Unfavorable CMR Baseline
Overall survival is markedly better for the 33% of patients (blue) with a favorable CMR proﬁ
patients (green) without dyssynchrony by CURE (CURE 0.70). The remaining patients (re
other abbreviations as in Figure 1.mechanical and scar-related characterization of the sub-
strate for resynchronization from the pre-procedure CMR,
with some additional discrimination provided by intra-
procedural characterization of electrical timing at the LVLP.
In addition, using models based on logistic, linear, and Cox
proportional hazards regression, we have shown strongProﬁles
le (CURE <0.70, no LVLP scar, delayed ECC onset at LVLP) compared with the 31% of
d) had intermediate survival. CRT-D ¼ cardiac resynchronization therapy deﬁbrillator;
Figure 6 Ventricular Tachycardia and Dyssynchrony
Patients receiving cardiac resynchronization therapy deﬁbrillator (CRT-D) without prominent dyssynchrony (CURE 0.60) had increased ventricular tachyarrhythmias (VTs)
compared with patients with CURE <0.60. Abbreviations as in Figure 1.
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both echocardiographic CRT response and clinical events.
For example, the third of the patients with a favorable CMR
proﬁle (CURE <0.70, delayed onset of ECC at the LVLP,
and absence of scar at the LVLP) enjoyed a 12-fold higher
survival rate than the group of patients with CURE 0.70.
In addition, none of the patients with CURE 0.70 had
a CRT response (100% negative predictive value). The
remaining patients had intermediate outcomes. In this
way, this analysis has identiﬁed 3 distinct groups of pa-
tients expected to have a 0% CRT response and decreased
survival after CRT, 100% CRT response and improved
survival after CRT, or intermediate outcomes. With respect
to other clinical events, increased ventricular tachyar-
rhythmia events in patients with higher CURE may have
occurred because these patients did not have the beneﬁcial
antiarrhythmic effect of LV functional improvement to
outweigh the potentially proarrhythmic effects of LV
epicardial pacing (24).
The association between delayed onset of ECC at the
LVLP and CRT response was likely due to resynchroniza-
tion of the most dysfunctional LV myocardium, allowing
that tissue to contribute much more effectively to overall
pump function. Furthermore, the use of time to strain onset
rather than time to peak strain at the LVLP may be bene-
ﬁcial considering that the corresponding assessments of
electrical timing are also measured during early systole rather
than near the end of systole where late strain peaks occur.
The independent contributions from regional mechanical
and electrical activation are noteworthy. Furthermore, theﬁnding that scar at the LVLP was associated with CRT
nonresponse is distinguished from prior reports (9,25) by the
strength of association between LVLP scar and CRT
response even after adjustment for overall dyssynchrony and
other mechanical and electrical characteristics at the LVLP,
which was determined using quantitative methods.
Last, the success of our models may be attributed to some
extent to the high-quality strain data that was obtained with
CMR cine DENSE, as demonstrated in previous studies
(5,8,15). In addition, use of the CURE parameter is ad-
vantageous because it does not introduce potential errors in
the manual detection of regional time to peak strain, as seen
with other dyssynchrony parameters, as we have shown
previously (8). Of note, other echocardiographic modalities,
such as 3-dimensional echocardiography, offer high-quality
ECC data, and we have demonstrated that CURE can be
effectively determined from 3-dimensional echocardiography
(26), such that its use is not limited to CMR. From a more
general perspective, these results have high clinical signiﬁ-
cance for improving patient selection and outcomes after
CRT, with potential associated cost savings.
Study limitations. We did not prospectively test the effect
of altering the lead position based on CMR ﬁndings.
Additional factors could have been analyzed, but the purpose
of the study was to develop a parsimonious model including
key factors related to scar, mechanical activation, and elec-
trical timing. Regarding follow-up, although the primary
outcomes measure was reduction in LVESV at 6 months,
there was signiﬁcant variation in the follow-up durations for
clinical outcomes such as overall survival, and this was
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analysis. Regarding the study cohort, patients were enrolled
at a single institution, such that there may be differences
between patients at this institution and other institutions
receiving CRT. In addition, although this patient cohort
provides strong evidence for this model, a large, prospective,
multicenter trial would be appropriate prior to widespread
clinical use.
Conclusions
Mechanical, electrical, and scar properties at the LVLP
together with CMR mechanical dyssynchrony are strongly
associated with echocardiographic CRT response and clin-
ical events after CRT. Modeling these ﬁndings in patients
referred for CRT holds promise for improving outcomes
after the procedure.
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